Does Rallies show Form 4 insider transactions for INMB?

Yes. Rallies tracks INMB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is INMB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INMB. It does not provide personalized investment advice.

INMB (INmune Bio Inc. Common stock) Stock Analysis - Insider Trades

INmune Bio Inc. Common stock (INMB) is a publicly traded Healthcare sector company. As of May 21, 2026, INMB trades at $1.42 with a market cap of $39.61M and a P/E ratio of -0.75. INMB moved -0.71% today. Year to date, INMB is -5.37%; over the trailing twelve months it is -81.64%. Its 52-week range spans $1.09 to $11.64. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces INMB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading INMB stock inside the company?

Recent INMB insider activity includes Moss David J bought 10.00K, Tesi Raymond Joseph bought 15.38K, Moss David J bought 7.69K, Juda Scott bought 5.00K, and Moss David J bought 18.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

INMB Key Metrics

Key financial metrics for INMB
Metric	Value
Price	$1.42
Market Cap	$39.61M
P/E Ratio	-0.75
EPS	$-1.86
Dividend Yield	0.00%
52-Week High	$11.64
52-Week Low	$1.09
Volume	1.35K
Avg Volume	0
Revenue (TTM)	$50.00K
Net Income	$-45.93M
Gross Margin	0.00%

Recent INMB Insider Trades

Moss David J bought 10.00K (~$52.87K) on Sep 30, 2024.
Tesi Raymond Joseph bought 15.38K (~$98.05K) on Sep 12, 2024.
Moss David J bought 7.69K (~$49.02K) on Sep 12, 2024.
Juda Scott bought 5.00K (~$36.35K) on Jun 25, 2024.
Moss David J bought 18.03K (~$149.99K) on Apr 19, 2024.

Latest INMB News

INmune Bio Expands CORDStrom Collaboration with Anthony Nolan, Securing Long-Term Cord Supply for RDEB, Oncology and Inflammation — May 5, 2026
INmune Bio Impairs $16.5M Asset, Completes Prostate Cancer Trial Under Budget — Mar 31, 2026
INmune Bio Raises $27.5M, Targets Mid-Summer UK MAA Filing for CORDStrom Therapy — Mar 30, 2026
INmune Bio Schedules Feb 26 Webinar to Unveil Phase III RDEB CORDStrom Data — Feb 19, 2026
INmune Bio Files MHRA Pre-Submission Package for CORDStrom Program — Feb 11, 2026

INMB Analyst Consensus

3 analysts cover INMB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.

Common questions about INMB

Who is trading INMB stock inside the company?: Recent INMB insider activity includes Moss David J bought 10.00K, Tesi Raymond Joseph bought 15.38K, Moss David J bought 7.69K, Juda Scott bought 5.00K, and Moss David J bought 18.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for INMB?: Yes. Rallies tracks INMB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is INMB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INMB. It does not provide personalized investment advice.